Advertisement

Deborah Christensen, RN, BSN, HNB-BC

Intermountain Southwest Cancer Center
St. George, UT
Authored Items
Seasoned Navigator: A Case Study on Care Transitions in Genomic Testing and Timely Treatment Decision-Making
Cheryl Bellomo, MSN, RN, HON-ONN-CG, OCN, Deborah Christensen, RN, BSN, HNB-BC, Tricia Strusowski, RN, MS
Articles & White Papers published on April 19, 2016 in Evidence into Practice, Breast Cancer
Along with the diagnosis of breast cancer comes many decisions regarding treatment options. Oncotype DX, a genomic/gene expression assay, provides quantitative assessment of chemotherapy benefit and risk of distant recurrence in early-stage estrogen receptor–positive (ER+), HER2/neu-negative breast cancer to assist in developing individualized treatment plans.
Learn More
Last modified: March 10, 2021

Back to Top

 

ASSOCIATION

 

MEMBERSHIP

 
Visit the Website
Visit the Website

Privacy Policy   |   Terms of Use
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators®   |   PO Box 563, Cranbury, NJ 08512   |    This email address is being protected from spambots. You need JavaScript enabled to view it.   |    732-992-1532
AONN+ DBA AONN+ is a 501(c)(6) organization under federal tax guidelines. AONN+ Foundation for Learning, Inc. a 501(c)(3) organization under federal tax guidelines.
AONN+ Advantage, LLC, a wholly owned subsidiary of AONN+.